One study loaded the MYC gene-targeted CRISPR/Cas9 system into anti-CD19-CARsEVs, which accumulated in CD19-positive tumour cells rapidly and efficiently targeted the MYC oncogene [235]. This evidence concerns the gene MYC and neoplasm.